Literature DB >> 26622103

Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts.

Christopher Molvar1, Robert Lewandowski2.   

Abstract

Hepatocellular carcinoma (HCC) is a lethal tumor, claiming over half a million lives per year. Treatment of HCC is commonly performed without curative intent, and palliative options dominate, including catheter-based therapies, namely, transarterial chemoembolization and yttrium-90 ((90)Y) radioembolization. This review will showcase the performance of (90)Y radioembolization for the treatment of HCC, focusing on recent seminal data and technical advances. In particular, novel radioembolization treatment concepts are discussed and compared with conventional HCC therapy.

Entities:  

Keywords:  hepatocellular carcinoma; interventional radiology; liver cancer; radioembolization; therapy

Year:  2015        PMID： 26622103      PMCID： PMC4640917          DOI： 10.1055/s-0035-1564704

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN： 0739-9529            Impact factor:   1.513


  65 in total

1.  Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres.

Authors:  Renaud Lhommel; Larry van Elmbt; Pierre Goffette; Marc Van den Eynde; François Jamar; Stanislas Pauwels; Stephan Walrand
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-04-27       Impact factor: 9.236

Review 2.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

3.  Mortality and hospital utilization for hepatocellular carcinoma in the United States.

Authors:  W Ray Kim; Gregory J Gores; Joanne T Benson; Terry M Therneau; L Joseph Melton
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

Review 4.  Early detection and curative treatment of early-stage hepatocellular carcinoma.

Authors:  Masatoshi Kudo
Journal:  Clin Gastroenterol Hepatol       Date:  2005-10       Impact factor: 11.382

5.  Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization.

Authors:  Kent Sato; Robert J Lewandowski; James T Bui; Reed Omary; Russell D Hunter; Laura Kulik; Mary Mulcahy; David Liu; Howard Chrisman; Scott Resnick; Albert A Nemcek; Robert Vogelzang; Riad Salem
Journal:  Cardiovasc Intervent Radiol       Date:  2006 Jul-Aug       Impact factor: 2.740

6.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

Review 7.  Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.

Authors:  D Zorzi; A Laurent; T M Pawlik; G Y Lauwers; J-N Vauthey; E K Abdalla
Journal:  Br J Surg       Date:  2007-03       Impact factor: 6.939

8.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

9.  Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.

Authors:  Michael Vouche; Laura Kulik; Rohi Atassi; Khairuddin Memon; Ryan Hickey; Daniel Ganger; Frank H Miller; Vahid Yaghmai; Michael Abecassis; Talia Baker; Mary Mulcahy; Ritu Nayar; Robert J Lewandowski; Riad Salem
Journal:  Hepatology       Date:  2013-10-01       Impact factor: 17.425

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425
View more
  2 in total

Review 1.  Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma.

Authors:  Valerie J W Tong; Vishal G Shelat; Yew Kuo Chao
Journal:  J Clin Transl Res       Date:  2021-11-06

Review 2.  PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.

Authors:  M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-12       Impact factor: 9.236
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.